Project information
Molecular-genetic markers for prediction of radiotherapy response in head and neck cancer
- Project Identification
- 16-29835A (kod CEP: NV16-29835A)
- Project Period
- 4/2016 - 12/2019
- Investor / Pogramme / Project type
-
Ministry of Health of the CR
- Ministry of Health Research Programme 2015 - 2022
- MU Faculty or unit
- Faculty of Medicine
- Cooperating Organization
-
Institute of Biophysics
St. Anne's University Hospital Brno
- Responsible person Rom Kostřica
Currently, there is no clinical marker which allows a pre-therapeutic selection of patients with head and neck tumors that would profit more from the conservative therapy or primary surgery, respectively. In this project, we will focus on this "First Therapy Dilemma" by developing the Ionizing Radiation Induced Foci staining method to evaluate the radiosensitivity of individual tumors. The relative radioresistance of tumors will be assessed by comparing their repair capacity and cell death with peripheral blood lymphocytes isolated from the same patient or with the “healthy” tissue adjacent to the tumor. This method may reveal the patients hypersensitive to gamma-rays, estimate the maximum acceptable radiotherapy dose, assess a responsiveness of tumors to replication stress, and elucidate effectiveness of alternative irradiation regimes as well as provide a tool to select patients profitable from proton therapy. The main aim of this project is then development of a cost-efficient, fast, robust, and easy to perform diagnostics method with a large room for automation.
Publications
Total number of publications: 25
2016
-
Negative Pressure Wound Therapy in the Treatment of Chylousfistula after Neck Dissection
ARC Journal of Surgery, year: 2016, volume: 2, edition: 2
-
Předléčebné stanovení radiosenzitivity nádorů hlavy a krku
Year: 2016, type: Conference abstract
-
Předléčebné stanovení radiosenzitivity nádorů hlavy a krku, cesta k individualizované terapii?
Year: 2016, type: Conference abstract
-
Relation of viral etiology of oropharyngeal tumors to the response rate of treatment modalities
Year: 2016, type: Appeared in Conference without Proceedings
-
Two New Faces of Amifostine: Protector from DNA Damage in Normal Cells and Inhibitor of DNA Repair in Cancer Cells
Journal of Medicinal Chemistry, year: 2016, volume: 59, edition: 7, DOI